Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROSSING: Tezepelumab in eosinophilic esophagitis
NL-OMON53940Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tezepelumab in eosinophilic esophagitis (EoE) (3 arms), sponsored by AstraZeneca. Primary endpoints: Histologic response and Symptom improvement. Started Apr 2023; status: recruiting.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON53940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53940.